Acute pyelonephritis might be complicated by the formation of renal and perirenal abscesses and very rarely by renal vein thrombosis, which is a life-threatening condition. The main causative agents of acute pyelonephritis are enterobacteriaceae with the incidence of extended-spectrum beta-lactamase (ESBL)-producing strains increasing worldwide. We present the case of a 71-year-old Greek man with history of diabetes mellitus and recent hospitalization, who suffered from severe pyelonephritis with renal abscesses formation and associated bacteraemia caused by ESBL-producing Escherichia coli, complicated by extensive thrombosis of the ipsilateral renal vein and its branches, protruding also in the inferior venal cava. Our patient was effectively treated with anticoagulants and targeted antibiotic therapy, respectively, consisted of low molecular weight heparin transitioned to oral acenocoumarol for 3 months and 2-week course of intravenous meropenem followed by oral fosfomycin for additional 3 weeks as quidded by clinical and computed tomographic follow-up. In conclusion, in complicated urinary infections, caused by ESBL-producing enterobacteriaceae, oral fosfomycin might represent an effective option for step-down therapy of carbapenems, allowing the shortness of the duration of patient’s hospitalization and carbapenem use.
This is a preview of subscription content, log in to check access
Compliance with ethical standards
Conflict of interest
The authors have declared that no conflict of interest exists.
This article does not contain any studies with human participants performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
Yildiz H, Van Nieuwenhove S, Doyen M, Yombi JC. Acute pyelonephritis and renal vein thrombosis: a case report and review of the literature. J Infect Chemother. 2016;22:759–61.CrossRefPubMedGoogle Scholar
Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682–90.CrossRefPubMedGoogle Scholar
Doi Y, Bonomo RA, Hooper DC, Kaye KS, Johnson JR, Clancy CJ, et al. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis. 2017;64:S30–S35.CrossRefPubMedGoogle Scholar
Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int. 1985;28:429–39.CrossRefPubMedGoogle Scholar
Kumar S, Singh SK, Mavuduru RS, Acharya NC, Agarwal MM, Jha VK, et al. Acute pyelonephritis with renal vein and inferior vena cava thrombosis in a case of hyperhomocysteinemia. Int Urol Nephrol. 2009;41:185–8.CrossRefPubMedGoogle Scholar
Kawano PR, Yamamoto HA, Gerra R, Garcia PD, Contti MM, Nga HS, et al. A case report of venous thrombosis after kidney transplantation—we can save the graft? Time is the success factor. Int J Surg Case Rep. 2017;36:82–5.CrossRefPubMedPubMedCentralGoogle Scholar
Harris LA, Van Every MJ, Fundell LJ. Acute bilateral renal vein thrombosis secondary to sepsis from pyelonephritis. Int Braz J Urol. 2012;38:132–4.CrossRefPubMedGoogle Scholar
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–52.CrossRefPubMedGoogle Scholar
Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016;29:583–94.CrossRefPubMedGoogle Scholar
Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem therapy is associated with improved survival compared with piperacillin–tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–25.PubMedPubMedCentralGoogle Scholar